NCT06056570: A trial that was reported late by Urica Therapeutics Inc.
This trial has reported, although it was 20 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT06056570 |
|---|---|
| Title | A Phase 1B Open Label Evaluation of the PK and PD of Dotinurad and Drug-Drug Interaction of Dotinurad and Allopurinol in U.S. Patients with Gout and Hyperuricemia |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Oct. 4, 2023 |
| Completion date | June 27, 2024 |
| Required reporting date | June 27, 2025, midnight |
| Actual reporting date | July 17, 2025 |
| Date last checked at ClinicalTrials.gov | May 29, 2026 |
| Days late | 20 |